Thursday 22 August 2019

Kidney Cancer Diagnostics Market Intelligence Study for Comprehensive Insights- NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina Inc.

Kidney cancer is a type of cancer which starts in kidney cells. Two major types of kidney cancer include transitional cell carcinoma (TCC) and renal cell carcinoma (RCC). Different types of kidney cancer get developed in different ways which imply different long-term outcomes. This cancer originates in two principal locations of the kidney – the renal pelvis and the renal tubule.

Ask for sample link here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=56

A new report published by Fact.MR estimates the global kidney cancer diagnostics market to exhibit an impressive expansion at during the forecast period 2017 to 2022. In terms of revenues, the global market for kidney cancer diagnostics will reach nearly US$ 700 Mn by 2022-end.

Targeted Systemic Therapies for Metastatic Kidney Cancer are Providing Significant Benefits to Survival and Progression

Over the past few years, the diagnosis and management of kidney cancer, or, renal cell carcinoma (RCC), have undergone tremendous transformations. A number of discoveries, studies, and trails are being taken in renal mass biopsy, minimally-invasive thermal ablation, and active surveillance, owing to the surge in diagnosis rate of small renal masses, usually in patients with high morbidity risks related to operative treatment. In addition, targeted systemic therapies associated with metastatic kidney cancer have replaced cytokine-based treatment, providing significant benefits to survival and progression. Recent trails and reviews have cemented the partial nephrectomy’s role as the standard diagnosis-based surgical management option for majority of low-stage masses, and roles of adrenalectomy and lymphadenectomy pertaining to nephrectomy. These incidences are estimated to augment growth of the global kidney cancer diagnostics market.

View Full Report@:-
https://www.factmr.com/report/56/kidney-cancer-diagnostics-market

Kidney cancer has been witnessed to occur majorly in older population. Diagnosis of kidney cancer becomes an intricate task, considering the condition of geriatric patients. While staple diagnostic technologies such as MRI and CT scan continue to play a pivotal role in the global market, patients are also expecting the emergence of all-inclusive diagnosis tests. Medical organizations are also funneling high investments in R&D of kidney cancer diagnostics, particularly to improve the precision of early stage diagnosis tests. Through advancements in medical technology, the global market for kidney cancer diagnostics is also expected to witness emergence of new tests that can simultaneously decelerate the pace of tumor maturation between multiple stages of kidney cancer.

Hospital-associated Labs will Remain Preferred for Kidney Cancer Diagnostics


On the basis of end-users, hospital-associated labs are estimated to remain preferred for kidney cancer diagnostics, accounting for the largest revenues by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global kidney cancer diagnostics market. In addition, cancer research institutes are expected to register the highest CAGR in the market through 2022.

Request for the Customization of the report: https://www.factmr.com/connectus/sample?flag=RC&rep_id=56

North America to Remain the Largest Market for Kidney Cancer Diagnostics

In terms of revenues, North America is expected to remain the largest market for kidney cancer diagnostics, followed by Europe. However, kidney cancer diagnostics market in Europe will exhibit a comparatively higher CAGR than North America during the forecast period. In addition, Asia Pacific excluding Japan (APEJ) will continue to be the fastest expanding market for kidney cancer diagnostics through 2022.

Competition Tracking

Myriad Genetics Inc, NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina, Inc., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc., and Abbott Laboratories are observed as key players in the global market for kidney cancer diagnostics.

About Us

We are an insights-driven global market intelligence company with a unique purpose: enabling organizations make better decisions. We do this by creating an ecosystem where an eclectic cognitive collaboration between human imagination and data science leads to path breaking ideas.

Our vision is to foster a pervasive culture where critical business decisions are taken on the basis of facts rather than assumptions and perceptions.

Our mission is empowerment – empowerment of free-thought; empowerment of fact-based decisions; empowerment of decisive action.

For More Information Kindly Contact: 

Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Tel: +353-1-4434-232
Mail: sales@factmr.com
Read Blog: https://theheraldmedia.com/

No comments:

Post a Comment